Akero Therapeutics, Inc.

NasdaqGS AKRO

Akero Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -81,990.14%

Akero Therapeutics, Inc. EBITDA Margin is -81,990.14% for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: AKRO

Akero Therapeutics, Inc.

CEO	Dr. Andrew Cheng M.D., Ph.D.
IPO Date	June 20, 2019
Location	United States
Headquarters	601 Gateway Boulevard
Employees	60
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Key trends

Past 5 years